Nautilus Biotechnology (NAUT) Change in Account Payables (2020 - 2026)
Nautilus Biotechnology (NAUT) reported Change in Account Payables of $200000.0 for Q1 2026, up 252.67% on a YoY basis from $56710.0 in Q1 2025, and up 9900.0% sequentially from $2000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Change in Account Payables (2020 - 2026) Analysis & Trends
Nautilus Biotechnology (NAUT) has 7 years of Change in Account Payables data on file, last reported at $200000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 252.67% year-over-year to $200000.0; the trailing twelve-month figure through Mar 2026 stood at $262000.0 (up 132.63% YoY), and the FY2025 full-year result was -$69000.0, up 88.06% from the prior year.
- Change in Account Payables rose to $200000.0 in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $371000.0 in Q4 2023 to a low of -$543000.0 in Q4 2024.
- A 5-year average of -$36176.5 and a median of $2000.0 in 2025 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables slumped 25000.0% in 2022 and surged 252.67% in 2026, its largest moves.
- Tracing NAUT's Change in Account Payables over 5 years: stood at $289000.0 in 2022, then grew by 28.37% to $371000.0 in 2023, then tumbled by 246.36% to -$543000.0 in 2024, then soared by 100.37% to $2000.0 in 2025, then soared by 9900.0% to $200000.0 in 2026.
- Business Quant data shows NAUT's Change in Account Payables at $200000.0 in Q1 2026, $2000.0 in Q4 2025, and -$20000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Nautilus Biotechnology | 212.11 Mn | 116.24 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Dec 31, 2024 | -543,000.00 |
| Dec 31, 2024 | -543,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | -402,000.00 |
| Jun 30, 2024 | -402,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Dec 31, 2023 | 371,000.00 |
| Dec 31, 2023 | 371,000.00 |